ReviewLung2026
Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases.
Review in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRespiratory infections remain a major global health burden despite advances in systemic antimicrobial therapy. Antimicrobial dry powder inhalers (DPIs) have emerged as precision-engineered pulmonary delivery platforms capable of achieving high local drug concentrations while minimizing systemic toxicity.
objectiveThis review examines the historical evolution, pharmacological landscape, particle engineering technologies, translational challenges, and clinical progress of antibacterial, antiviral, and antifungal DPIs. CONTENT: We trace the evolution of antimicrobial DPIs from early aerosolized therapies to contemporary engineered systems, integratingdisease targets, pharmacological agents, particle and formulation engineering, inhaler technologies, patents, clinical development andregulatory milestones. Particular emphasis is placed on formulations supported by in vivo efficacy, clinical investigation or regulatoryapproval, highlighting advances in tuberculosis, chronic bacterial infections, viral respiratory diseases and pulmonary fungal infections.
conclusionsAntimicrobial DPIs are evolving toward precision pulmonary therapies, highlighting their expanding role in chronic infections, pandemic preparedness, and next-generation pulmonary anti-infective therapy. Overcoming dose, deposition, stability, andtranslational barriers will be critical for broader clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.